AIM ImmunoTech (NYSE: AIM) presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists. Dr. Pawel Kalinski's presentation highlighted Ampligen's unique two-level selectivity when combined with PD-1 blockade or chemotherapy. The drug demonstrated the ability to:
1. Selectively induce CTL-attracting chemokines without triggering counterproductive Treg-attracting chemokines
2. Preferentially activate cancer tissues over healthy tissues
The research showed that Ampligen's selective impact on tumor microenvironment stems from its ability to avoid helicase-dependent activation of NFkB, differentiating it from poly-I:C and other TLR ligands.
AIM ImmunoTech (NYSE: AIM) ha presentato i dati di uno studio clinico sul suo farmaco Ampligen durante l'Assemblea Annuale dell'American Association of Immunologists. La presentazione del Dr. Pawel Kalinski ha evidenziato la selettività a due livelli unica di Ampligen quando combinato con il blocco di PD-1 o la chemioterapia. Il farmaco ha dimostrato la capacità di:
1. Indurre selettivamente chemochine che attirano CTL senza attivare chemochine che richiamano Treg, che sarebbero controproducenti
2. Attivare preferenzialmente i tessuti tumorali rispetto a quelli sani
La ricerca ha mostrato che l'impatto selettivo di Ampligen sul microambiente tumorale deriva dalla sua capacità di evitare l'attivazione di NFkB dipendente dall'elicasa, distinguendolo da poly-I:C e altri ligandi TLR.
AIM ImmunoTech (NYSE: AIM) presentó datos de un ensayo clínico de su medicamento Ampligen en la Reunión Anual de la American Association of Immunologists. La presentación del Dr. Pawel Kalinski destacó la selectividad única de dos niveles de Ampligen cuando se combina con bloqueo de PD-1 o quimioterapia. El medicamento demostró la capacidad de:
1. Inducir selectivamente quimioquinas que atraen CTL sin activar quimioquinas que atraen Treg, lo cual sería contraproducente
2. Activar preferentemente tejidos cancerosos sobre tejidos sanos
La investigación mostró que el impacto selectivo de Ampligen en el microambiente tumoral se debe a su capacidad para evitar la activación de NFkB dependiente de helicasa, diferenciándolo de poly-I:C y otros ligandos TLR.
AIM ImmunoTech(NYSE: AIM)는 미국 면역학회 연례회의에서 자사 약물 Ampligen의 임상시험 데이터를 발표했습니다. Pawel Kalinski 박사의 발표에서는 PD-1 차단제 또는 화학요법과 병용 시 Ampligen의 독특한 이중 수준 선택성이 강조되었습니다. 이 약물은 다음과 같은 능력을 보여주었습니다:
1. 역효과를 일으키는 Treg 유인 화학주성분을 유발하지 않고 CTL 유인 화학주성분을 선택적으로 유도
2. 정상 조직보다 암 조직을 우선적으로 활성화
연구 결과, Ampligen이 종양 미세환경에 선택적으로 영향을 미치는 이유는 헬리케이스 의존적 NFkB 활성화를 피하는 능력에 있으며, 이는 poly-I:C 및 기타 TLR 리간드와 구별됩니다.
AIM ImmunoTech (NYSE: AIM) a présenté des données d'essais cliniques pour son médicament Ampligen lors de la réunion annuelle de l'American Association of Immunologists. La présentation du Dr Pawel Kalinski a mis en avant la sélectivité unique à deux niveaux d'Ampligen lorsqu'il est combiné avec un blocage de PD-1 ou une chimiothérapie. Le médicament a démontré sa capacité à :
1. Induire sélectivement des chimiokines attirant les CTL sans déclencher de chimiokines attirant les Treg, ce qui serait contre-productif
2. Activer préférentiellement les tissus cancéreux plutôt que les tissus sains
La recherche a montré que l'impact sélectif d'Ampligen sur le microenvironnement tumoral provient de sa capacité à éviter l'activation de NFkB dépendante de l'hélicase, ce qui le différencie du poly-I:C et d'autres ligands TLR.
AIM ImmunoTech (NYSE: AIM) stellte klinische Studiendaten zu seinem Medikament Ampligen auf dem Jahrestreffen der American Association of Immunologists vor. Dr. Pawel Kalinskis Präsentation hob Ampligens einzigartige zweistufige Selektivität hervor, wenn es in Kombination mit PD-1-Blockade oder Chemotherapie eingesetzt wird. Das Medikament zeigte die Fähigkeit:
1. Selektiv CTL-anziehende Chemokine zu induzieren, ohne kontra-produktive Treg-anziehende Chemokine auszulösen
2. Krebsgewebe gegenüber gesundem Gewebe bevorzugt zu aktivieren
Die Forschung zeigte, dass Ampligens selektive Wirkung auf das Tumormikroumfeld auf seiner Fähigkeit beruht, eine helicaseabhängige Aktivierung von NFkB zu vermeiden, wodurch es sich von poly-I:C und anderen TLR-Liganden unterscheidet.
Positive
Ampligen demonstrated selective activation of cancer tissues while sparing healthy tissues
The drug showed unique dual-selectivity in clinical trials
Ampligen avoided triggering undesirable inflammatory and suppressive factors
Negative
None.
OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent Annual Meeting of the American Association of Immunologists held May 3-7, 2025, in Honolulu, HI.
The paper, titled “Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of the TME,” discussed the unique two-level selectivity of action of Ampligen when used as a part of chemokine modulation and combined with PD-1 blockade or chemotherapy. Dr. Kalinski discussed the preclinical data and data from recently completed clinical trials showing the ability of Ampligen to selectively induce the desirable CTL-attracting chemokines, but not the counterproductive Treg-attracting chemokines, which differentiated it from poly-I:C. The second level of selectivity was the preferential activation of cancer tissues, rather than healthy tissues. The mechanistic data discussed by Dr. Kalinski indicate that the selectivity of Ampligen’s impact on the tumor microenvironment result from its avoidance of helicase-dependent activation of NFkB. This allows Ampligen to avoid the induction of TNFα and other NFkB-dependent undesirable inflammatory and suppressive factors, which are commonly induced by poly-I:C and other TLR ligands, and to focus its impact on the tumor tissues, which display elevated levels of endogenous NFkB.
AIM CEO Thomas K. Equels commented: “These findings and Dr. Kalinski’s analysis further support our belief in the potential of Ampligen as a powerful therapeutic for unmet medical needs, including deadly cancers.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in oncology. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ
What are the key findings about AIM ImmunoTech's Ampligen drug presented at the immunology conference?
The key findings showed Ampligen's unique two-level selectivity: it selectively induces CTL-attracting chemokines without triggering Treg-attracting chemokines, and preferentially activates cancer tissues over healthy tissues.
How does AIM's Ampligen differ from poly-I:C in cancer treatment?
Ampligen avoids helicase-dependent activation of NFkB, preventing the induction of TNFα and other undesirable inflammatory factors commonly triggered by poly-I:C, allowing more focused impact on tumor tissues.
What is the mechanism of action for AIM ImmunoTech's Ampligen in treating cancer?
Ampligen works through a two-level selective mechanism, inducing desirable CTL-attracting chemokines while avoiding Treg-attracting chemokines, and preferentially targeting cancer tissues due to their elevated NFkB levels.
What potential applications does AIM stock's Ampligen drug target?
According to AIM's CEO, Ampligen shows potential as a therapeutic for unmet medical needs, particularly in treating deadly cancers.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
